Stockreport

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics, Inc.  (GANX) 
PDF Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial [Read more]